Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - SuperQ Quantum Computing Inc. QBTQ (FSE: 25X) (OTCQB: QBTQF) ("SuperQ Quantum", "SuperQ", or the "Company"),  has entered into a commercial agreement with Science & Humans  ("S&H"), a Canadian hormonal health company and a recipient of the Deloitte Technology Fast 50 recognition in 2025, to deploy quantum-AI powered clinician solutions  for S&H. Under the agreement, SuperQ will architect and deliver AI  clinicians enhanced by quantum computing based optimization for S&H  to integrate into its real-world healthcare workflows.

Addressing Challenges of Increased Clinical Demands

S&H  is an Ontario-based provider of hormonal healthcare including  menopause, thyroid conditions, sexual health and more. It has been  experiencing significant user growth and is one of the Deloitte's  Technology Fast 50 companies this year. S&H requires autonomous  systems such as diagnostic and treatment AI to keep up with the  increased demand. High accuracy and speed are key considerations for  this sensitive life sciences use case. S&H's scientific and clinical  teams are providing the domain expertise and knowledge base for these  systems.

SuperQ is building these systems  for S&H through its professional services and Super™ platform, which  enables development of quantum-AI products. Super™ implements  interoperability across quantum hardware types (annealing, gate-based,  hybrid classical/quantum) and integrates high-performance classical  compute, AI-driven orchestration and quantum processing. This "gateway"  approach enables enterprises and healthcare institutions to leverage  emerging quantum architectures along with GPU-based AI pipelines without  being locked into a single hardware ecosystem.

Aftab  Pashaw, CEO of S&H, commented: "We are excited to be the first to  explore frontier AI and quantum technologies in clinical diagnosis and  treatment. SuperQ is playing a key role in the development, integration  and enhancement of our clinical AI systems. Together, we have already  reached the MVP stage and aim to reach full production in the coming  months."

Strategic Implications in the Backdrop of NVIDIA Announcements

The  recent unveiling of NVIDIA's NVQLink interconnect at NVIDIA GTC DC  marks a pivotal shift in how quantum and classical compute  infrastructure will collaborate, a shift that directly amplifies the  strategic value of SuperQ's Super™ platform. NVIDIA is now doing at the  hardware level what SuperQ has been doing at the software level -  interlacing classical and quantum computing to create real-world value.

The "Quantum,  AI and High-performance Computing: intersection Opportunities" meetup  organized by Dr. Khan at the NVIDIA GTC explored this coupling in  detail. The participants agreed that we have entered a hybrid  classical-quantum reality. NVIDIA's hardware announcements reinforce  SuperQ's vision of driving commercial value from hybrid compute. Super™  gateway platform is purpose-built to orchestrate classical compute, AI  pipelines and multiple quantum hardware types (annealing, gate-based,  hybrid), especially in sensitive industries like healthcare where  reliability, interpretability and speed are non-negotiable.

"Commercial  use cases for the Super™ platform and related professional services are  growing by the day," said Dr. Muhammad Khan, CEO & Board Chair of  SuperQ. "The Science & Humans project signals that quantum-AI is now  ready to transform clinician workflows, where the margin for error is  minimal and the stakes are highest."

Project Highlights

SuperQ  will architect and deliver quantum-AI clinician systems in domains  where accuracy, interpretability and reliability are paramount -  including patient triage, autonomous monitoring, treatment optimisation  and decision-support in sensitive care environments.

The initial roadmap entails a phased-deployment approach:

• Triaging patients and enhancing diagnostic decision-support.

• Streamlining prescription workflows.

• Extending into chronic disease management, real-time patient monitoring and broader healthcare-system logistics.

Science  & Humans brings recognised clinical and scientific domain strength  to the collaboration. Notably, Science & Humans was ranked No. 32 on  Deloitte Canada's 2025 Technology Fast 50 list, reflecting 970% growth  over the prior three years.

This agreement  complements SuperQ's recent hardware-and‐software roadmap expansion,  including the launch of its Super™ hybrid quantum-classical platform and  the initiation of quantum-hardware development - positioning SuperQ as one of the few, if not the first, bridging quantum-AI architecture with  commercial-healthcare solutions.

About SuperQ Quantum Computing Inc.

SuperQ Quantum Computing Inc. QBTQ (FSE: 25X) (OTCQB: QBTQF) is defining the next era of enterprise  transformation, looking to emerge as a partner for global organizations  seeking direct quantum and supercomputing ROI previously beyond reach.  We are looking to position ourselves as the trusted leader in quantum  and supercomputing-powered problem-solving and optimization.

Our  flagship Super™ platform strives to make the most advanced  computational power intuitive and accessible. This will empower  executives, leading research institutions, and critical government  agencies to unlock immediate business impact across finance, healthcare,  logistics, defense, and beyond, leveraging our proprietary AI  Autopilots to turn complex challenges into executive-ready results with  one-click productization and deployment. SuperQ Quantum is headquartered  in Canada with a growing international presence, particularly in the  US, Middle East and Asia, strategically establishing Super Hubs in key  regions.

For further information contact:

Dr. Muhammad Khan, CEO of SuperQ Quantum Computing Inc.

Email: info@superq.co

Telephone: +1 587 889 1918

www.superq.co

Cautionary Statement Regarding Forward-Looking Information

This  press release contains forward-looking information within the meaning  of Canadian securities legislation. Forward-looking information  generally refers to information about an issuer's business, capital, or  operations that is prospective in nature. Any statements that are  contained in this press release that are not statements of historical  fact may be deemed to be forward-looking information. Forward-looking  information is often identified by terms such as "may", "should",  "anticipate", "would", "will", "estimates", "believes", "intends"  "expects" and similar expressions which are intended to identify  forward-looking information. More particularly and without limitation,  this press release contains forward-looking information concerning  statements with respect to the closing of the Offering, timing of  closing of the Offering, the use of proceeds of the Offering and the  future plans of the Company. The Company cautions that all  forward-looking information is inherently uncertain, and that actual  performance may be affected by a number of material factors,  assumptions, expectations and risks, many of which are beyond the  control of the Company, including but not limited to assumptions  regarding prevailing market conditions and general business, economic,  competitive, political and social uncertainties to develop the  forward-looking information in this press release, as well as those risk  factors discussed or referred to in the Company's disclosure documents  filed with the securities regulatory authorities in certain provinces of  Canada and available at www.sedarplus.com. There can be no assurance  that such information will prove to be accurate, as actual results and  future events could differ materially from those anticipated in such  information. Accordingly, readers should not place undue reliance on  forward-looking information.

The  forward-looking information contained in this press release are made as  of the date of this press release, and the Company does not undertake  any obligation to update publicly or to revise any of the included  forward-looking information, whether as a result of new information,  future events or otherwise, except as expressly required by applicable  securities laws.

Neither the Canadian  Securities Exchange nor its Market Regulator (as that term is defined in  the policies of the Canadian Securities Exchange) accepts  responsibility for the adequacy or accuracy of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273020